Co-Diagnostics, Inc. filings document a molecular diagnostics company’s operating results, material events, governance actions, and capital-structure disclosures. Recent 8-K filings cover financial results, Regulation FD disclosures, non-GAAP presentation references, Nasdaq listing-rule matters, and other corporate events tied to the company’s common stock.
Proxy and material-event filings also describe shareholder voting matters, including authorization for a reverse stock split, along with governance procedures and security-structure changes. The filing record links the company’s Co-Dx PCR platform, clinical and regulatory disclosures, commercialization activities, and public-company reporting obligations with risk, liquidity, listing, and ownership-related disclosure categories.
Co-Diagnostics, Inc. reported a weak first quarter of 2026, with total revenue of $145,954 and a net loss of $9.14 million compared to a $7.53 million loss a year earlier. Cost of revenue exceeded sales, leading to a negative gross margin, while operating expenses rose to $9.16 million on higher research and development and legal and professional costs.
Cash and cash equivalents fell to $8.23 million at March 31, 2026, after using $7.85 million in operating cash in the quarter, partially offset by $4.33 million raised through an at-the-market stock program. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months, reflecting dependence on new financing and future profitability.
Co-Diagnostics, Inc. reported first-quarter 2026 revenue of $0.15 million, up from $0.05 million a year earlier, but remained deeply loss-making. Operating expenses were $9.2 million, leading to an operating loss of $9.2 million and a net loss of $9.1 million, or $4.06 per share, compared with a $7.5 million loss, or $7.05 per share, in 2025.
Cash and cash equivalents were $8.2 million as of March 31, 2026, down from $11.9 million at year-end, while adjusted EBITDA loss widened to $8.7 million from $7.4 million. Management highlighted regulatory and commercial progress, including an Indian CDSCO license and ISO 13485 certification for the CoSara PCR Pro instrument, expansion of South Asian distribution to a roughly $13 billion market, and preparation for a 510(k) submission for an upper respiratory multiplex test and TB clinical studies in India.
Co-Diagnostics, Inc. registered a shelf to offer up to $150,000,000 of securities from time to time, including common stock, preferred stock, debt securities, warrants, units and rights.
The prospectus states each offering will be described in a separate prospectus supplement and that net proceeds are intended for working capital and general corporate purposes, with possible uses including product development, sales and marketing expansion, acquisitions and debt repayment.
Co-Diagnostics, Inc. (CODX) files its annual report describing a specialty PCR diagnostics business while warning of substantial doubt about its ability to continue as a going concern. The company develops lab-based and point-of-care PCR tests, including a Co-Dx PCR Pro platform still awaiting key regulatory clearances.
CODX reports cash and cash equivalents of $11.9 million and an accumulated deficit that widened to $80.4 million, reflecting ongoing losses. It is funding operations through grants and at-the-market equity programs and highlights significant dependence on a few customers and granting agencies. Extensive risk factors cover regulation, competition, supply-chain reliance, data privacy, and the need for additional capital to advance its multiplex respiratory and global infectious disease testing strategy.
Co-Diagnostics reported sharply weaker 2025 results. Revenue fell to $0.6 million from $3.9 million in 2024, mainly from lower grant revenue, while an $18.9 million intangible impairment helped drive an operating loss of $50.2 million and a net loss of $46.9 million, or $35.25 per share.
Adjusted EBITDA loss improved to $28.0 million from $33.5 million, but cash, cash equivalents and marketable securities dropped to $11.9 million from $29.7 million, reducing financial flexibility. Management highlighted progress on its PCR platform, AI-enabled Primer Ai platform, and joint ventures CoSara in India and CoMira in Saudi Arabia, including new patents and regional expansion agreements.
Co-Diagnostics, Inc. reports that Nasdaq has confirmed the company is back in compliance with the $1.00 minimum bid price and other requirements for continued listing on The Nasdaq Capital Market. Trading in its securities is scheduled to resume on Nasdaq with the market open on March 11, 2026.
Nasdaq’s Hearing Panel will monitor the company for one year, through March 9, 2027; if the closing bid price stays below $1.00 for 30 consecutive business days, a delisting determination would be issued, subject to appeal. The company also preliminarily estimates cash and cash equivalents of about $11.9 million as of December 31, 2025, an unaudited figure that may change after year-end closing procedures.
Co-Diagnostics, Inc. received an amended Schedule 13G/A from Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri reporting that they now beneficially own 0 shares of the company’s common stock, or 0% of the class.
The percentages are based on 60,892,582 shares of common stock outstanding as of November 11, 2025, as stated in Co-Diagnostics’ Form 10-Q. The filers state that any securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Co-Diagnostics, Inc. reports that Nasdaq has determined to delist its common stock from The Nasdaq Capital Market because the company has not met the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading in its shares is scheduled to be suspended on January 14, 2026, and the stock is expected to trade on the Pink Limited Information tier of the OTC Market under the symbol CODX.
The company plans to request a hearing before a Nasdaq Hearings Panel and notes that, after a 1-for-30 reverse stock split effective January 2, 2026, its closing bid price has been at or above $1.00 per share. If it maintains at least a $1.00 closing bid for 10 consecutive business days ending January 15, 2026, it will seek a compliance determination and cancellation of the hearing, though there is no assurance it will regain compliance or avoid the trading suspension.
Co-Diagnostics, Inc. (CODX) director equity update: A company director reported the vesting and issuance of 57,499 shares of common stock on 11/23/2025 at a stated price of $0.00, reflecting settlement of previously granted restricted stock units under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. After this transaction, the director beneficially owns 281,666 shares of common stock and 170,834 restricted stock units. The RSUs referenced stem from awards of 40,000 units on January 17, 2023, 70,000 units on June 12, 2023, 110,000 units on April 26, 2024, and 125,000 units on August 13, 2025, each vesting in six equal installments every six months from their respective commencement dates.
Co-Diagnostics, Inc. reported an insider equity transaction by its Chief Financial Officer, Brian L. Brown. On 11/23/2025, Brown had 134,167 restricted stock units convert into common stock at an exercise price of $0.00. Following this vesting event, he beneficially owned 599,355 shares of Co-Diagnostics common stock directly.
On the same date, 40,723 shares of common stock were sold at a price of $0.35 per share. The filing explains that these shares were sold solely to cover tax withholding obligations related to the vesting of restricted stock units under the company’s long-term incentive plan and did not represent a discretionary trade by Brown.